CD73 promote cervical cancer growth via EGFR/AKT1 pathway

被引:6
|
作者
Liu, Chong [1 ]
Gao, Zhao-Wei [1 ]
Wang, Xi [1 ]
Lin, Fang [1 ]
Zhang, Hui-Zhong [1 ]
Dong, Ke [1 ]
机构
[1] Air Force Mil Med Univ, Tangdu Hosp, Dept Clin Diag, Xian, Peoples R China
基金
中国国家自然科学基金;
关键词
CD73; cervical cancer; growth; EGFR; AKT1; PROGNOSTIC BIOMARKER; ECTO-5-NUCLEOTIDASE; EXPRESSION; CETUXIMAB; FAILURE;
D O I
10.21037/tcr-21-2446
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Cervical cancer ranks third in cancer incidence worldwide and is the most frequent gynecological cancer in developing countries, explore the molecular mechanism of cervical cancer and to find effective treatment has become the focus of medical workers. CD73 has been implicated in the progression of many cancers. However, the study of CD73 in cervical cancer has not been reported. The aim of this study was to identify the effect and mechanism of CD73 overexpression on cervical cancer growth in vitro and in vivo. Methods: Cervical cancer cell models with CD73 overexpression were construction by using lentiviruses infection in Hela and SiHa cells. Cell???s proliferation was investigated by using xCELLigence real-time cell analysis (RTCA) system. Murine xenograft models were used to evaluate the effect of CD73 overexpression on tumor growth in vivo. Small interfering RNA (siRNA) transfection were used to suppress expression levels of EGFR and AKT1. Cell cycle and apoptosis were evaluated by flow cytometry (FCM). Results: CD73 overexpression significantly promoted cervical cancer cells proliferation in vitro and tumor growth in vivo. The expression levels of EGFR and AKT1 were significantly increased in cell models and transplanted tumor tissues with CD73 overexpression. And moreover, knockdown of EGFR and AKT1 could inhibit proliferation of CD73 overexpressed cell models via inducing cell apoptosis and cell cycles increased in G2/M phase and reduction of G1 phase. Furthermore, the expression levels of CDK2, CDK3 and CDKN1A, which are cell cycle regulated molecules, were significantly increased in CD73 overexpressed cells with EGFR/AKT1 knockdown. Conclusions: Our data demonstrated that CD73 overexpression promote cervical cancer growth in vitro and in vivo, via activating EGFR/AKT1 pathway.
引用
收藏
页码:1089 / 1098
页数:10
相关论文
共 50 条
  • [21] Blockade of CD73 potentiates radiotherapy antitumor immunity and abscopal effects via STING pathway
    An, Ran
    Wu, Chao
    Tang, Cunyu
    Zhang, Chen
    Han, Feiru
    Xu, Zeen
    Zou, Yiping
    Wang, Jun
    Yuan, Zhiyong
    Jiang, Shengpeng
    Liu, Lijie
    Huang, Chongbiao
    Tao, Zhen
    CELL DEATH DISCOVERY, 2024, 10 (01)
  • [22] Loss of CD73 Promotes the Growth of Uterine Leiomyomas via ADORA2B-Regulated AKT Signaling Pathways.
    Guo, Xiaofang
    Okuka, Maja
    Borresen, Brittney
    Semerci, Nihan
    Martin, Naya
    Guzeloglu-Kayisli, Ozlem
    Kayisli, Umit
    Anderson, Matthew L.
    REPRODUCTIVE SCIENCES, 2023, 30 : 225A - 225A
  • [23] Glucocorticoid Receptor β Stimulates Akt1 Growth Pathway by Attenuation of PTEN
    Stechschulte, Lance A.
    Wuescher, Leah
    Marino, Joseph S.
    Hill, Jennifer W.
    Eng, Charis
    Hinds, Terry D., Jr.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (25) : 17885 - 17894
  • [24] Mesenchymal stromal cells derived from cervical cancer tumors induce an increase of CD73 expression in cervical cancer cells
    Avila Ibarra, L. R.
    Mora Garcia, M. D. L.
    Hernandez Montes, J.
    Garcia Rocha, R.
    Weiss-Steider, B.
    Monroy Garcia, A.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2016, 46 : 215 - 215
  • [25] CD73 DOWNREGULATION INHIBIT IN VITRO AND IN VIVO GLIOBLASTOMA GROWTH THROUGH ADENOSINERGIC PATHWAY.
    Azambuja, J. H.
    Gelsleichter, N. E.
    Lenz, G.
    Beckenkamp, L. R.
    Iser, I. C.
    Sevigny, J.
    Oliveira, F. H.
    Stefani, M. A.
    Spanevello, R. M.
    Wink, M. R.
    Battastini, A. M. O.
    PURINERGIC SIGNALLING, 2018, 14 : S79 - S80
  • [26] Tiamulin inhibits breast cancer growth and pulmonary metastasis by decreasing the activity of CD73
    Xu Yang
    Shimin Pei
    Huanan Wang
    Yipeng Jin
    Fang Yu
    Bin Zhou
    Hong Zhang
    Di Zhang
    Degui Lin
    BMC Cancer, 17
  • [27] CD73 downregulation by EGFR-targeted liposomal CD73 siRNA potentiates antitumor effect of liposomal doxorubicin in 4T1 tumor-bearing mice
    Anvar Soleimani
    Farshad Mirzavi
    Sara Nikoofal-Sahlabadi
    Amin Reza Nikpoor
    Bita Taghizadeh
    Mehdi Barati
    Mohammad Soukhtanloo
    Mahmoud Reza Jaafari
    Scientific Reports, 12
  • [28] CD73 downregulation by EGFR-targeted liposomal CD73 siRNA potentiates antitumor effect of liposomal doxorubicin in 4T1 tumor-bearing mice
    Soleimani, Anvar
    Mirzavi, Farshad
    Nikoofal-Sahlabadi, Sara
    Nikpoor, Amin Reza
    Taghizadeh, Bita
    Barati, Mehdi
    Soukhtanloo, Mohammad
    Jaafari, Mahmoud Reza
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [29] Tiamulin inhibits breast cancer growth and pulmonary metastasis by decreasing the activity of CD73
    Yang, Xu
    Pei, Shimin
    Wang, Huanan
    Jin, Yipeng
    Yu, Fang
    Zhou, Bin
    Zhang, Hong
    Zhang, Di
    Lin, Degui
    BMC CANCER, 2017, 17
  • [30] Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target
    Le, Xiuning
    Negrao, Marcelo, V
    Reuben, Alexandre
    Federico, Lorenzo
    Diao, Lixia
    McGrail, Daniel
    Nilsson, Monique
    Robichaux, Jacqulyne
    Munoz, Irene Guijarro
    Patel, Sonia
    Elamin, Yasir
    Fan, You-Hong
    Lee, Won-Chul
    Parra, Edwin
    Soto, Luisa Maren Solis
    Chen, Runzhe
    Li, Jun
    Karpinets, Tatiana
    Khairullah, Roohussaba
    Kadara, Humam
    Behrens, Carmen
    Sepesi, Boris
    Wang, Ruiping
    Zhu, Mingrui
    Wang, Linghua
    Vaporciyan, Ara
    Roth, Jack
    Swisher, Stephen
    Haymaker, Cara
    Zhang, Jianhua
    Wang, Jing
    Wong, Kwok-Kin
    Byers, Lauren A.
    Bernatchez, Chantale
    Zhang, Jianjun
    Wistuba, Ignacio I.
    Gibbons, Don L.
    Akbay, Esra A.
    Heymach, John, V
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : 583 - 600